NICE recommends earlier use of Roche’s RoActemra for rheumatoid arthritis – PMLiVE
 USA TODAY | NICE recommends earlier use of Roche's RoActemra for rheumatoid arthritis PMLiVE ... for people with RA as a third-line treatment option if DMARDs had been ineffective, and if patients had also both demonstrated an inadequate response to one or more TNF inhibitors and could not take another Roche drug, MabThera (rituximab). Green light for earlier use of rheumatoid arthritis drug |
Pixantrone Progresses Toward Approval in the European Union – Medscape
Pixantrone Progresses Toward Approval in the European Union Medscape In addition, the CHMP noted that the benefit of pixantrone appeared to be lower in patients who had used rituximab in the past, and that its benefit was not established when used as a fifth round of chemotherapy, or later, in patients whose disease did ... |
Pixantrone Progresses Toward Approval in the European Union – Medscape
Pixantrone Progresses Toward Approval in the European Union Medscape In addition, the CHMP noted that the benefit of pixantrone appeared to be lower in patients who had used rituximab in the past, and that its benefit was not established when used as a fifth round of chemotherapy, or later, in patients whose disease did ... |
Progressive Sclerodermoid Skin Changes—Diagnosis – Archives of Dermatology
Progressive Sclerodermoid Skin Changes—Diagnosis Archives of Dermatology Our patient was referred to a major regional cancer center and underwent systemic chemotherapy with 5 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab. Over the course of treatment, her skin softened, ... |
Dr. Myhill’s notes on fatigue, the immune system’s energy demands, and Rituximab – ProHealth
Dr. Myhill's notes on fatigue, the immune system's energy demands, and Rituximab ProHealth Rituximab is primarily used in cancer chemotherapy. By pure chance a patient who had severe ME received this drug as part of a treatment for her lymphoma and her ME symptoms disappeared. She was delighted! Her daily energy bucket was no longer being ... |
Town and Country Doctor Pleads Guilty To Receiving Misbranded Cancer Drugs – Patch.com
Town and Country Doctor Pleads Guilty To Receiving Misbranded Cancer Drugs Patch.com Generally, “Mabthera” does contain Rituximab, the same active ingredient found in the FDA-approved drug legally used and marketed in the United States called Rituxan®. However, the drug ordered by Dr. Nisar came from an unregistered drug establishment ... |
Pharmacyclics/Janssen Biotech’s PCI-32765 Has Earned Decision Resources … – EON: Enhanced Online News (press release)
Pharmacyclics/Janssen Biotech's PCI-32765 Has Earned Decision Resources ... EON: Enhanced Online News (press release) Rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo's Rituxan/MabThera) will continue to dominate a more fragmented diffuse large B-cell lymphoma market over the forecast period, despite the entry of less-expensive biosimilar versions of rituximab. |
EMA Grants Conditional Approval Of Pixuvri For B-Cell Lymphoma – Wall Street Journal
EMA Grants Conditional Approval Of Pixuvri For B-Cell Lymphoma Wall Street Journal -Conditional approval will be renewed on a yearly basis until the obligation to provide additional data on rituximab-pretreated patients has been fulfilled. -Applicant, CTI Life Sciences Ltd., has informed the Committee that it expects to be able to ... European Medicines Agency's Committee For Medicinal Products For Human Use ... |
FDA and Roche Warn of Counterfeit Avastin – Pharmaceutical Technology Magazine (blog)
FDA and Roche Warn of Counterfeit Avastin Pharmaceutical Technology Magazine (blog) Nor have other products including Faslodex (fulvestrant), Neupogen (filgrastim), Rituxan (rituximab) and Herceptin (trastuzumab) available from unapproved suppliers been in short supply. The identification of a counterfeit cancer drug (probably ... |
CORRECTING and REPLACING Pharmacyclics/Janssen Biotech’s PCI-32765 Has Earned … – MarketWatch (press release)
CORRECTING and REPLACING Pharmacyclics/Janssen Biotech's PCI-32765 Has Earned ... MarketWatch (press release) Rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo's Rituxan/MabThera) will continue to dominate a more fragmented diffuse large B-cell lymphoma market over the forecast period, despite the entry of less-expensive biosimilar versions of rituximab. |